Company Overview and News

1
MSB / Mesabi Trust 8-K (Current Report)

2018-10-11 sec.gov - 1
msb_Current_Folio_8K
MSB

 
MSB / Mesabi Trust PRE 14A

2018-10-05 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS
MSB

 
MSB / Mesabi Trust 8-K

2018-10-05 sec.gov
UNITED STATES
MSB

 
MSB / Mesabi Trust 8-K (Current Report)

2018-10-05 sec.gov
UNITED STATES
MSB

107
Jane's August Dividend Increases And Income Tracker - Retirement Accounts

2018-09-28 seekingalpha
This is the sixth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $689.45.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL

20
John And Jane's August Dividend Increases And Income Tracker - Taxable Account

2018-09-13 seekingalpha
August marks the 10th month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $1,665.95.
SOJA GIS XOM IDCC SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI WLKP ENB ETP HP ORI SPG WPC ADM

 
MSB / Mesabi Trust 10-Q (Quarterly Report)

2018-09-07 sec.gov
msb_Current_Folio_10Q
MSB

109
Jane's July Dividend Increases And Income Tracker - Retirement Accounts

2018-08-21 seekingalpha - 2
This is the fifth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,610.61.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL

14
John And Jane's July Dividend Increases And Income Tracker - Taxable Account

2018-08-13 seekingalpha
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM

 
MSB / Mesabi Trust 8-K (Current Report)

2018-07-30 sec.gov
msb_Current_Folio_8K UNITED STATES
MSB

83
Jane's June Dividend Increases And Income - Retirement Accounts

2018-07-19 seekingalpha - 2
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL

21
John And Jane: June Dividend Income Tracker - Taxable Account

2018-07-16 seekingalpha
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA GIS XOM IDCC SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP HP ORI SPG WPC ADM

 
MSB / Mesabi Trust 8-K (Current Report)

2018-07-13 sec.gov
msb_Currenr_Folio_8K
MSB

35
29 'Safer' Dividend Financials Boast 5.77% To 13.71% Summer Yields

2018-06-25 seekingalpha
Top 10 Financial Services "safer" dividend stocks, by broker one-year targets, averaged 14.4% in predicted one-year net as of 6/22/18.
AIY AINV MVC APO APAM AAALY MVCD MVCB AZIHF TCRX WBC MSB WEBNF AZIHY AIB WBK TCRD TCRZ TSLF OCSI WBC AAALF SLFPY

358
Jane's May Dividend Income Tracker - Retirement Accounts

2018-06-19 seekingalpha
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG DUKH GD TRV MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 590672101